The Swiss drugmaker is buying rights to the Chinese biotech's experimental drug as it tries to catch Eli Lilly and Novo Nordisk in obesity.
Recap by typeshit. Full story at tradersunion.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
The poster says nausea and vomiting rates in the UBT251 trial look identical and may make it seem easier to tolerate than rivals. It's one user's analysis.
A new analysis in a South American medical journal suggests GLP-1 medications may be linked to improvements. The full report has the details.
Loading…